Autoantibodies before, during and after administration of recombinant interferon-alpha for chronic viral hepatitis. 1995

E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
Disciplina de Gastroenterologia, Escola Paulista de Medicina, São Paulo, Brasil.

This study was undertaken to investigate the presence of autoantibodies in patients with chronic viral hepatitis B and C, before, during and after interferon-alpha (IFN-alpha) therapy and to study their relation to dose and type of IFN-alpha and response to treatment. Fifty patients with chronic hepatitis were divided in two groups, a control-group of 21 patients (10 type B and 11 type C) who were followed for 6 months without treatment and an IFN-group consisting of 29 patients (8 type B and 21 type C) who received IFN therapy for 6 months. Serum samples were tested for a range of antibodies at the start of the study, during therapy and at the end of the 6 month period. Antibodies tested for included: antinuclear, smooth muscle, antimitochondrial, parietal cell and thyroid microsomal. Four (8%) of the total patient group had autoantibodies at the beginning of the study (two in each group). During the follow-up period no patient in the control group developed antibodies compared with 3 (11%) patients in the treatment group. Autoantibodies developed in patients treated with higher doses of IFN and were found in those patients who tended to show a poor response to IFN-therapy. Further studies are needed to establish the relationship between poor response to IFN-alpha and development of autoantibodies.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection

Related Publications

E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
February 1993, The American journal of gastroenterology,
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
June 1991, Journal of medical virology,
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
December 2002, Journal of endocrinological investigation,
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
January 1992, Acta medica Austriaca,
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
November 1990, Journal of hepatology,
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
July 1994, Deutsche medizinische Wochenschrift (1946),
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
March 1998, Annals of internal medicine,
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
September 1994, La Revue du praticien,
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
July 1989, Hepatology (Baltimore, Md.),
E P Lopes, and A E Silva, and H Sette Junior, and R X Guimarães, and M L Ferraz
January 1992, Archives of virology. Supplementum,
Copied contents to your clipboard!